JAC Advance Access originally published online on March 2, 2005
Journal of Antimicrobial Chemotherapy 2005 55(4):420-423; doi:10.1093/jac/dki056
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading article |
Topical microbicides for the prevention of genital herpes infection
Departments of 1 Medicine and 2 Pediatrics, Division of Infectious Diseases, Mount Sinai School of Medicine, New York, NY, USA
* Correspondence address. Division of Infectious Diseases, 1 Gustave L. Levy Place, Box 1090, New York, NY 10029, USA. Tel: +1-212-241-5272; Fax: +1-212-426-4813; Email: betsy.herold{at}mssm.edu
Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is the most common cause of genital ulcers. Despite increased public awareness and the initiation of efforts to prevent transmission, the prevalence of herpes simplex virus (HSV) type 2 continues to increase. What makes HSV so difficult to control is that most sexual and perinatal transmission occurs during unrecognized or asymptomatic shedding. The impact of genital herpes as a public health threat is amplified because of its epidemiological synergy with HIV/AIDS. Thus, there is an urgent need for novel prophylactic methods, such as topical microbicides designed for genital application, to prevent both HSV and HIV transmission. Several candidate microbicides are being advanced to clinical trials based on in vitro activity and animal studies. These include compounds that inactivate virus directly, those that enhance innate immunity, and drugs that block viral binding and entry. A more vigorous evaluation of the safety of these and other candidate topical microbicides in development should include assessment of the impact of repeated application on innate host defences in the genital tract.
Keywords: HIV , HSV , innate immunity
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. Pinna, P. Oreste, T. Coradin, A. Kajaste-Rudnitski, S. Ghezzi, G. Zoppetti, A. Rotola, R. Argnani, G. Poli, R. Manservigi, et al. Inhibition of Herpes Simplex Virus Types 1 and 2 In Vitro Infection by Sulfated Derivatives of Escherichia coli K5 Polysaccharide Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3078 - 3084. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. I. Bernstein, N. Goyette, R. Cardin, E. R. Kern, G. Boivin, J. Ireland, J.-M. Juteau, and A. Vaillant Amphipathic DNA Polymers Exhibit Antiherpetic Activity In Vitro and In Vivo Antimicrob. Agents Chemother., August 1, 2008; 52(8): 2727 - 2733. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Artemenko, E. N. Muratov, V. E. Kuz'min, N. A. Kovdienko, A. I. Hromov, V. A. Makarov, O. B. Riabova, P. Wutzler, and M. Schmidtke Identification of individual structural fragments of N,N'-(bis-5-nitropyrimidyl)dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds J. Antimicrob. Chemother., July 1, 2007; 60(1): 68 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Saidi, J. Eslaphazir, C. Carbonneil, L. Carthagena, M. Requena, N. Nassreddine, and L. Belec Differential Modulation of Human Lactoferrin Activity against Both R5 and X4-HIV-1 Adsorption on Epithelial Cells and Dendritic Cells by Natural Antibodies J. Immunol., October 15, 2006; 177(8): 5540 - 5549. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Yim, C. J. Carroll, A. Tuyama, N. Cheshenko, M. J. Carlucci, D. D. Porter, G. A. Prince, and B. C. Herold The Cotton Rat Provides a Novel Model To Study Genital Herpes Infection and To Evaluate Preventive Strategies J. Virol., December 1, 2005; 79(23): 14632 - 14639. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Cheshenko, W. Liu, L. M. Satlin, and B. C. Herold Focal Adhesion Kinase Plays a Pivotal Role in Herpes Simplex Virus Entry J. Biol. Chem., September 2, 2005; 280(35): 31116 - 31125. [Abstract] [Full Text] [PDF] |
||||




